Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14063688 | 0.90 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL16393150 | 0.86 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPK1HIF1A | |
| SCHEMBL2735591 | 0.86 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPK1HIF1A | |
| SCHEMBL1200060 | 0.86 | FOLH1 (0.71) | FOLH1SMN1; SMN2KDM4EMAPK1HIF1A | |
| SCHEMBL7915392 | 0.86 | FOLH1 (0.56) | FOLH1SMN1; SMN2 | |
| SCHEMBL7915383 | 0.86 | FOLH1 (0.56) | FOLH1SMN1; SMN2 | |
| SCHEMBL20018424 | 0.84 | FOLH1 (0.83) | FOLH1 | |
| SCHEMBL20724702 | 0.84 | FOLH1 (0.74) | FOLH1SMN1; SMN2 | |
| SCHEMBL15290484 | 0.84 | FOLH1 (0.54) | FOLH1SMN1; SMN2 | |
| SCHEMBL17849920 | 0.84 | FOLH1 (1.00) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885SMN1; SMN2 1375/4885KDM4E 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.